Michael Risbano, MD

Trials

Studies that name Michael Risbano, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:20 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT07223528 · TEPH: Telaglenastat Efficacy in Pulmonary Hypertension

  Chan, Stephen, MD, PhD · not yet recruiting · Pulmonary Hypertension · principal investigator
• N/A
  NCT03905083 · miRNA and Myokines in Patients With PAH

  University of Pittsburgh · withdrawn · Pulmonary Arterial Hypertension · principal investigator
• Ph2
  NCT03629340 · Metformin for Pulmonary Hypertension HFpEF

  University of California, San Francisco · completed · Pulmonary Hypertension, Heart Failure · principal investigator
• Ph2
  NCT03015402 · Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

  University of Pittsburgh · completed · Pulmonary Hypertension Secondary, Heart Failure · principal investigator
• N/A
  NCT01581086 · Vascular Subphenotypes of Lung Disease in HIV & COPD

  University of Pittsburgh · completed · Pulmonary Artery Hypertension · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 08:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Phase II Trial of Metformin for Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction
  R01AG058659 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARC A SIMON · fiscal years 2018 to 2022
  Named on NCT03629340
• Therapeutic Targeting of Vascular Subphenotypes of Lung Disease
  P01HL103455 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Alison Morris · fiscal years 2011 to 2020
  Named on NCT03015402